Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonardo Calza

Showing results (101-110 of 188) with videos related to

Pageof 19
Sort By:
AIDS Patient Care and Stds|September 11, 2009
Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogueLeonardo Calza, Roberto Manfredi, Vincenzo Colangeli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 14, 2025
Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level ViremiaLeonardo Calza, Vincenzo Colangeli, Maddalena Giglia, et al.
Infectious Diseases (London, England)|December 27, 2019
No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-upLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
International Journal of STD & AIDS|August 11, 2023
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experienceLeonardo Calza, Vincenzo Colangeli, Giulia Pensalfine, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 7, 2021
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/AbacavirLeonardo Calza, Giorgio Legnani, Ciro Fulgaro, et al.
AIDS (London, England)|June 17, 2005
Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot studyLeonardo Calza, Vincenzo Colangeli, Roberto Manfredi, et al.
Health Science Reports|January 10, 2019
Comparison of the Aptima HIV-1 Quant Dx assay with the COBAS AmpliPrep/COBAS TaqMan HIV-1 v2.0 Test for HIV-1 viral load quantification in plasma samples from HIV-1-infected patientsSerena Longo, Isabella Bon, Giuseppina Musumeci, et al.
International Journal of STD & AIDS|June 9, 2016
Acute onset myopericarditis as unusual presentation of primary HIV infectionGiacomo Vandi, Leonardo Calza, Nicolò Girometti, et al.
The New Microbiologica|February 18, 2014
Prevalence of sub-clinical vertebral fractures in HIV-infected patientsMarco Borderi, Leonardo Calza, Vincenzo Colangeli, et al.
AIDS Research and Human Retroviruses|September 16, 2020
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/EmtricitabineLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
Pageof 19

Showing results (101-110 of 188) with videos related to

Sort By:
Pageof 19
AIDS Patient Care and Stds|September 11, 2009
Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogueLeonardo Calza, Roberto Manfredi, Vincenzo Colangeli, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 14, 2025
Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level ViremiaLeonardo Calza, Vincenzo Colangeli, Maddalena Giglia, et al.
Infectious Diseases (London, England)|December 27, 2019
No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-upLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
International Journal of STD & AIDS|August 11, 2023
Doravirine/lamivudine/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experienceLeonardo Calza, Vincenzo Colangeli, Giulia Pensalfine, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 7, 2021
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/AbacavirLeonardo Calza, Giorgio Legnani, Ciro Fulgaro, et al.
AIDS (London, England)|June 17, 2005
Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot studyLeonardo Calza, Vincenzo Colangeli, Roberto Manfredi, et al.
Health Science Reports|January 10, 2019
Comparison of the Aptima HIV-1 Quant Dx assay with the COBAS AmpliPrep/COBAS TaqMan HIV-1 v2.0 Test for HIV-1 viral load quantification in plasma samples from HIV-1-infected patientsSerena Longo, Isabella Bon, Giuseppina Musumeci, et al.
International Journal of STD & AIDS|June 9, 2016
Acute onset myopericarditis as unusual presentation of primary HIV infectionGiacomo Vandi, Leonardo Calza, Nicolò Girometti, et al.
The New Microbiologica|February 18, 2014
Prevalence of sub-clinical vertebral fractures in HIV-infected patientsMarco Borderi, Leonardo Calza, Vincenzo Colangeli, et al.
AIDS Research and Human Retroviruses|September 16, 2020
Short Communication: No Significant Increase in Body Fat Mass in Naive HIV-Infected Patients Starting Raltegravir Plus Tenofovir Disoproxil Fumarate/EmtricitabineLeonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
Pageof 19